It's time for new molecular insights in bladder cancer

Discover more

Give your oncologists results they can trust

The therascreen FGFR RGQ RT-PCR Kit is the first FDA-approved companion diagnostic (CDx) test to identify patients with cases of metastatic urothelial cancer (mUC) that harbor actionable FGFR alterations, for whom treatment with BALVERSA (erdafitinib) may be appropriate.

Download the flyer to learn more.

Find a lab offering this new FGFR test.
Find lab

Reliably detect actionable genetic alterations

The therascreen FGFR RGQ RT-PCR Kit is a unique molecular test to identify actionable genetic alterations in patients with mUC, who may be eligible for treatment with BALVERSA (erdafitinib), a new FGFR inhibitor drug. The kit detects two point mutations in exon 7 [p.R248C (c.742C>T) and p.S249C (c.746C>G)], two point mutations in exon 10 [p.G370C (c.1108G>T) and p.Y373C (c.1118A)] and two fusions (FGFR3:TACC3v1 and FGFR3:TACC3v3) in the FGFR3 gene in RNA samples derived from clinical formalin-fixed paraffin-embedded (FFPE) UC tissue.
Learn about Balversa

The tools you need to ensure patients receive the best individualized care

QIAGEN’s therascreen kits allow you to access relevant genomic information for each patient and use it to make the best treatment decisions possible.

Browse our products